Volume 63, Issue 1, Pages (January 2003)

Slides:



Advertisements
Similar presentations
Kamyar Kalantar-Zadeh  Kidney International 
Advertisements

Acid-base profile in patients on PD
Home care assistance and the utilization of peritoneal dialysis
Volume 59, Issue 2, Pages (February 2001)
Benefits of switching from a conventional to a low-GDP bicarbonate/lactate-buffered dialysis solution in a rat model  Siska Mortier, Dirk Faict, Norbert.
Chemokine response to febrile urinary tract infection
Volume 66, Issue 6, Pages (December 2004)
Linear and logistic regression analysis
Volume 57, Issue 6, Pages (June 2000)
Acid-base profile in patients on PD
Role of diuretics in the preservation of residual renal function in patients on continuous ambulatory peritoneal dialysis  James F. Medcalf, Kevin P.G.
Long-term follow-up of patients randomized to biocompatible or conventional peritoneal dialysis solutions show no difference in peritonitis or technique.
D. Teta, M. Maillard, G. Halabi, M. Burnier  Kidney International 
Volume 62, Issue 2, Pages (August 2002)
Volume 59, Issue 1, Pages (January 2001)
Volume 64, Pages S3-S12 (December 2003)
Volume 59, Issue 1, Pages (January 2001)
The risk of hospitalization and modality failure with home dialysis
3,4-di-deoxyglucosone-3-ene promotes leukocyte apoptosis
Volume 57, Issue 6, Pages (June 2000)
Volume 59, Issue 1, Pages (January 2001)
Fluid overload and residual renal function in peritoneal dialysis: the proof of the pudding is in the eating  Wim Van Biesen, Achim Jörres  Kidney International 
Volume 60, Issue 4, Pages (October 2001)
Volume 63, Issue 1, Pages (January 2003)
Kamyar Kalantar-Zadeh  Kidney International 
Volume 59, Issue 5, Pages (May 2001)
High volume peritoneal dialysis vs daily hemodialysis: A randomized, controlled trial in patients with acute kidney injury  D.P. Gabriel, J.T. Caramori,
Volume 60, Issue 5, Pages (November 2001)
Volume 78, Issue 6, Pages (September 2010)
Volume 58, Issue 1, Pages (July 2000)
George A. Kaysen, Burl R. Don
Abnormalities in lipoprotein metabolism in hemodialysis patients
S.G. John, N.M. Selby, C.W. McIntyre  Kidney International 
Volume 53, Issue 4, Pages (April 1998)
What really happens to people on long-term peritoneal dialysis?
Chemokine response to febrile urinary tract infection
Pharmacokinetics of icodextrin in peritoneal dialysis patients
Analysis of fluid transport pathways and their determinants in peritoneal dialysis patients with ultrafiltration failure  A. Parikova, W. Smit, D.G. Struijk,
Volume 54, Issue 6, Pages (January 1998)
Volume 67, Issue 1, Pages (January 2005)
Volume 73, Issue 9, Pages (May 2008)
Fractional clearance of high molecular weight proteins in conscious rats using a continuous infusion method  Melissa J. Burne, Tanya M. Osicka, Wayne.
Volume 93, Issue 9, Pages (November 2007)
Nephrology Crossword: Peritoneal Dialysis
Benefits of switching from a conventional to a low-GDP bicarbonate/lactate-buffered dialysis solution in a rat model  Siska Mortier, Dirk Faict, Norbert.
Volume 62, Issue 2, Pages (August 2002)
Volume 66, Issue 3, Pages (September 2004)
Volume 73, Pages S72-S75 (April 2008)
Higher serum C-reactive protein predicts short and long-term outcomes in peritoneal dialysis-associated peritonitis  N.-Y. Zalunardo, C.-L. Rose, I.W.Y.
Volume 64, Pages S84-S93 (December 2003)
Volume 59, Issue 6, Pages (June 2001)
Volume 60, Issue 2, Pages (August 2001)
Quality of life in peritoneal dialysis patients: Decline over time and association with clinical outcomes  Sr. Anne B. Bakewell, Rob M. Higgins, Mair.
Peter G. Blake, Arsh K. Jain, Sechelle Yohanna  Kidney International 
Kathy E. Sietsema, Antonino Amato, Sharon G. Adler, Eric P. Brass 
Phosphate binders on iron basis: A new perspective?
Avshalom Shostak, Valery Wajsbrot, Lazaro Gotloib  Kidney International 
Biocompatibility of icodextrin
Volume 64, Issue 1, Pages (July 2003)
Volume 59, Issue 2, Pages (February 2001)
Victoria R. Briggs, Badri M. Shrestha, Martin E. Wilkie 
Erratum Kidney International Volume 61, Issue 4, (April 2002)
Volume 65, Issue 1, Pages (January 2004)
Volume 61, Issue 1, Pages (January 2002)
The International Pediatric Peritonitis Registry: Starting to walk
Volume 59, Issue 1, Pages (January 2001)
Volume 55, Issue 3, Pages (March 1999)
Volume 58, Issue 4, Pages (October 2000)
Volume 57, Issue 4, Pages (April 2000)
Kidney and hypertension
Presentation transcript:

Volume 63, Issue 1, Pages 298-305 (January 2003) Glucose degradation products in PD fluids: Do they disappear from the peritoneal cavity and enter the systemic circulation?  Martin Zeier, Vedat Schwenger, Reinhold Deppisch, Ulrike Haug, Kai Weigel, U. Bahner, Christoph Wanner, H. Schneider, Thomas Henle, Eberhard Ritz  Kidney International  Volume 63, Issue 1, Pages 298-305 (January 2003) DOI: 10.1046/j.1523-1755.2003.00705.x Copyright © 2003 International Society of Nephrology Terms and Conditions

Figure 1 Generation of fluorescent advanced glycation end products (AGE) compounds during incubation of low glucose degradation products (GDP) and conventional peritoneal dialysis (PD) fluids. The generation of fluorescent AGE compounds is given as the percent increase of optical density (excitation 350/emission 430 nm) of unused low GDP (A; N = 6 for 1.5%, N = 6 for 2.5% glucose) and conventional (B; N = 6 for 1.5%, N = 6 for 2.5% glucose) PD fluid and fluid recovered after a 2 hour [N = 15 in each group (low and high GDP)] and 8 hour [N = 15 in each group (low and high GDP] peritoneal dwell, respectively. Symbols are: (▪) unused 2.5%; (▴) unused 1.5%; (♦) spent at 2 hours; (•) spent at 8 hours. For all corresponding comparisons, that is, unused fluids and fluids from different dwell times (2 vs. 8 hours) and ex vivo incubation times, respectively, generation of fluorescence was significantly lower with low GDP compared to conventional PD fluid (P < 0.05, paired data, Wilcoxon-test). These fluids contained 1.5% glucose. Kidney International 2003 63, 298-305DOI: (10.1046/j.1523-1755.2003.00705.x) Copyright © 2003 International Society of Nephrology Terms and Conditions

Figure 2 Plasma fluorescence during the low GDP and conventional PD fluid periods. Plasma fluorescence (OD 350/430nm arbitrary units × 103) is shown after a low GDP PD fluid period of 4 weeks (median 22.8) and after a conventional PD fluid period of 4 weeks (median 24.2). Data are given as individual patient data and as mean ± SEM. The difference was statistically significant (P < 0.05 Wilcoxon test for paired data). Kidney International 2003 63, 298-305DOI: (10.1046/j.1523-1755.2003.00705.x) Copyright © 2003 International Society of Nephrology Terms and Conditions

Figure 3 Molecular weight-specific analysis of fluorescent AGE in plasma shows representative characteristic plasma fluorescence peak patterns of patient R.P. after 4 weeks treatment with low GDP PD fluid (A) and of the same patient after 4 weeks treatment with conventional PD fluid (B). Tables displayed at the top of the panels give the values for the mean peak areas ± SD of all patients obtained after the respective study periods. A significant difference (*P < 0.05, paired data, Wilcoxon test) was found for the integrated peak area of the high-molecular-weight fraction (that is, retention time 18.8 seconds corresponding to albumin as shown by independent calibration samples). Kidney International 2003 63, 298-305DOI: (10.1046/j.1523-1755.2003.00705.x) Copyright © 2003 International Society of Nephrology Terms and Conditions

Figure 4 Plasma carboxymethyllysine concentration during the low GDP and conventional PD fluid periods. The concentration of carboxymethyllysine in plasma is seen after a low GDP PD fluid period and after a conventional PD fluid period of 8 weeks each. Data are given as individual patient data and as mean ± SD. The difference was statistically significant (P < 0.05) using the t test for paired data. Kidney International 2003 63, 298-305DOI: (10.1046/j.1523-1755.2003.00705.x) Copyright © 2003 International Society of Nephrology Terms and Conditions